Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media
NCT ID: NCT07322224
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2024-08-05
2025-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dietary Supplement Examined for Anti-ageing Effects
NCT06714162
Evaluation of Anti-oxidant, Anti-aging and Wellbeing Effects of a Novel Nutraceutical Formulation (HealthSpan)
NCT05202652
Safety & Efficacy of Extended Longevity Protocol
NCT05296993
The Effects of a Longevity Supplement on Aging and Photoaging
NCT05262036
Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women
NCT01598272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Longevity Protocol Arm
Participants received a structured, multi-modal longevity protocol consisting of lifestyle optimization, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM) prepared individually from peripheral blood-derived pro-regenerative cells. All participants received the same intervention schedule over a 17-week period.
Multi-Modal Longevity Protocol
The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-Modal Longevity Protocol
The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Generally good overall health as assessed by the study team
* Able and willing to provide written informed consent
* Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
* Able to comply with study procedures for the duration of the intervention and assessments
Exclusion Criteria
* Any condition requiring hospitalization or emergency medical intervention within the past 12 months
* Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
* Active infectious disease at enrolment
* Pregnancy or breastfeeding
* Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months
* Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
xLongevity
UNKNOWN
Wellbeing International Foundation
UNKNOWN
BlueBird Age Reversal SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esteban Ortega, MD
Role: PRINCIPAL_INVESTIGATOR
Wellbeing International Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wellbeing International Foundation
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BB-ART3-2024-PILOT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.